Image courtesy of Pixabay
The clinical trial space had one of its most significant disruptions in decades in the early days of the pandemic. Now, some clinical trials are normalizing, but decentralized clinical trials are also growing.
To learn more about what is likely on the horizon for clinical trials in 2022, we reached out to Jan Pieter Kappelle, VP of strategy of 4G Clinical. Kappelle is optimistic about continued growth of decentralized clinical trials and the spread of digitization throughout the supply chain.
1. DCT trial designs will continue to growThe adoption of decentralized clinical trials (DCT) surged in the early days of the pandemic. “When we started up in this pandemic almost two years ago, studies really ground to a halt,” Kappelle said. As drug companies scrambled to adapt, many embraced a direct-to-patient (DtP) model for patients.
Read more